Gilead­'s Trodelvy scores 'sur­prise' OS win in metasta­t­ic breast can­cer, but da­ta will wait for an up­com­ing con­fer­ence

Gilead Sci­ences said Mon­day morn­ing that Trodelvy is the first TROP-2 di­rect­ed ADC to show sta­tis­ti­cal­ly sig­nif­i­cant and “clin­i­cal­ly mean­ing­ful” re­sults in over­all sur­vival from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER